Company Dossier · Health Care
Sotera Health
- Russell 1000
- MidCap 400
What Sotera Health is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $1.22 billion, up 8.9% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.11 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.18 billion, up 20% from a year earlier.SEC EDGAR filings (XBRL)
- Latest earnings call or results release (August 6, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 7 outlook figures raised, 1 lowered, 1 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 24, 2026): 1 risk factor added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $24.0 million on the open market.SEC Form 4
- 319 institutional managers reported a position at June 30, 2026 (+20 on the quarter before).SEC Form 13F
- H-1B filings certified in Q3 2025: 1.U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Sotera Health yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 19, 2026LobbyingLobbying report (VAN NESS FELDMAN, LLP)third_quarter 2026
- Oct 19, 2026LobbyingLobbying report (VAN NESS FELDMAN, LLP)third_quarter 2026
- Aug 14, 20268-KDirector or officer changeItem 5.02
- Jul 16, 2026LobbyingLobbying report (VAN NESS FELDMAN, LLP)second_quarter 2026
- Jul 16, 2026LobbyingLobbying report (VAN NESS FELDMAN, LLP)second_quarter 2026
- May 22, 20268-KShareholder vote resultsItem 5.07
- May 20, 20268-KMaterial agreement signedItem 1.01
- May 13, 20268-KMaterial agreement terminatedItem 1.02
- May 5, 20268-KDirector or officer changeItem 5.02
- Apr 16, 2026LobbyingLobbying report (VAN NESS FELDMAN, LLP)first_quarter 2026
- Apr 16, 2026LobbyingLobbying report (VAN NESS FELDMAN, LLP)first_quarter 2026
- Mar 16, 20268-KDirector or officer changeItem 5.02
- Feb 24, 20268-KDirector or officer changeItem 5.02
- Feb 24, 202610-KAnnual report (10-K)1 risk factors added, 1 removed
- Feb 5, 20268-KDirector or officer changeItem 5.02
- Jan 15, 2026LobbyingLobbying report (VAN NESS FELDMAN, LLP)fourth_quarter 2025
- Jan 15, 2026LobbyingLobbying report (VAN NESS FELDMAN, LLP)fourth_quarter 2025
- Sep 18, 20258-KMaterial agreement signedItem 1.01
- May 23, 20258-KShareholder vote resultsItem 5.07
- Feb 27, 202510-KAnnual report (10-K)0 risk factors added, 1 removed
- Feb 27, 202410-KAnnual report (10-K)0 risk factors added, 1 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Bio-Techne TECH | $1.2B | $0.3B | Jun 30, 2026 |
| Guardant Health GH | $1.2B | −$0.2B | Jun 30, 2026 |
| Madrigal Pharmaceuticals MDGL | $1.3B | −$0.2B | Jun 30, 2026 |
| Insmed INSM | $1.1B | −$0.8B | Jun 30, 2026 |
| Haemonetics HAE | $1.4B | $0.3B | Jun 27, 2026 |
| HealthEquity HQY | $1.4B | $0.5B | Jul 31, 2026 |
| Tempus AI TEM | $1.4B | −$0.3B | Jun 30, 2026 |
| LivaNova LIVN | $1.5B | $0.1B | Jun 30, 2026 |
Identity
- SEC CIK
- 1822479